

CURRICULUM VITAE

MARTHA M'LISS WERLER, DSc, MPH

Date and Place of Birth: January 11, 1958, Minneapolis, MN

EDUCATION:

- 1985-1989 Boston University School of Public Health, Boston
D.Sc. in Epidemiology
- 1981-1983 University of Michigan School of Public Health, Ann Arbor
M.P.H. in Epidemiology
- 1976-1980 Boston College, Chestnut Hill, MA
B.S. in Biology

PROFESSIONAL EXPERIENCE:

- 7/14- Chair, Dept. of Epidemiology, Boston University School of Public Health
- 12/07- Professor of Public Health (Epidemiology and Biostatistics), School of Public Health, Boston University School of Medicine
- 9/07- Director, Boston University Reproductive, Perinatal, and Pediatric Epidemiology Training Program
- 11/98-12/07 Associate Professor of Public Health (Epidemiology and Biostatistics), School of Public Health, Boston University School of Medicine
- 7/96-11/98 Associate Research Professor, Boston University School of Public Health
- 4/90-6/95 Assistant Research Professor, Boston University School of Public Health
- 7/89- Epidemiologist, Slone Epidemiology Center, Boston University School of Medicine
- 2/86-6/89 Junior Epidemiologist, Slone Epidemiology Unit, Boston University School of Medicine
- 7/85-2/86 Biostatistician/Epidemiologist, Embryology-Teratology Unit, Mass. General Hospital, Boston, MA
- 7/83-6/85 Research Assistant, Embryology-Teratology Unit, Mass. General Hospital, Boston, MA

5/82-12/86 Independent research project, Pediatric Surgery, Mott Children's Hospital, Ann Arbor, MI

5/82-9/82 Epidemiology Intern, University of Minnesota, Minneapolis, MN

AWARDS & HONORS:

5/14 Godfrey P. Oakley, Jr Award – National Birth Defects Prevention Network

6/13-6/14 President, Society for Pediatric and Perinatal Epidemiologic Research

6/12 Society for Perinatal and Pediatric Epidemiology Research Mentoring Award

12/05 Boston University School of Public Health Excellence in Teaching Award

10/03 Distinguished Alumni Award – Boston University School of Public Health

3/01-9/01 Fogarty Senior International Fellowship (F06 W05567)

6/00 Clark Fraser New Investigator Award – Teratology Society

6/88 Society for Epidemiologic Research Student Workshop

GRANTS AWARDED:

NIH / NICHD R13 (Principal Investigator) 4/1/2014-3/31/2019
Society for Pediatric and Perinatal Epidemiologic Research \$6000
 This grant is to support the Society's annual meeting.

NIH / NICHD T32HD052458 (Principal Investigator) 7/1/2007-4/30/2017
BU Reproductive, Perinatal, and Pediatric Epidemiology Training Program. \$210,260.
 This grant supports pre-doctoral students with tuition, stipend, and other training-related expenses.

CDC/Massachusetts Department of Public Health (Co-Investigator) 09/01/13-08/30/18
BD-STEPS / MA Birth Defects Center of Excellence \$106,076
 This study is an extension of the National Birth Defects Prevention Study. The project involves collection of information on risk factors and epidemiologic analyses.

1 R21 HD072460-01 (Principal Investigator) 04/01/12-03/31/14
NIH / NICHD \$75,000
 Nested case-control study of maternal herpes viruses in relation to gastroschisis
 The goal of this exploratory project is to identify whether maternal herpes viruses are associated with gastroschisis, and whether a large-scale, clinically-oriented study is warranted to explore biologic mechanisms.

- 5 R01 DE011939-14 (Principal Investigator)** 07/01/97-06/30/15
 NIH / NIDCR \$652,840
 This project continues follow-up of children with and without hemifacial microsomia into their teen years to evaluate the psychosocial, neurocognitive, quality of life, sleep, and speech outcomes.
- 5 U01 DD000697-03 (Principal Investigator)** 09/30/10-09/29/14
 CDC \$158,882
 Risk factors for folic acid-resistant spina bifida
 It has been established that folic acid intake around the time of conception can prevent spina bifida, but the effect is not absolute. The goal of this study is to identify preventable risk factors for spina bifida that occurred among women who ingested the recommended amount of folic acid, using data collected in the Slone Epidemiology Center Birth Defects Study.
- CDC/Massachusetts Department of Public Health (Co-Investigator)** 09/01/96-11/30/13
 National Birth Defects Prevention Study/MA Birth Defects Center of Excellence \$290,192
 The major goals of this project are to continue a population-based system of case-control surveillance for birth defects in Massachusetts and to participate in the study methods and research agendas of the national study.
- NIH / NIEHS (Co-Investigator)** 04/01/07-03/31/11
 Nitrates, Nitrites, and Nitrosatable Drugs and Risk of Selected Birth Defects \$16,310
 This study used National Birth Defects Prevention Study data to determine whether medications and other exposures that produce n-nitroso compounds affect the risk of a range of birth defects. Dr. Jean Brender at Texas A&M University is Principal Investigator.
- NIH / NICHD (Principal Investigator)** 08/01/06-07/31/09
 Dietary Glycemic Load, Obesity, and Birth Defect Risks \$150,000
 This project examined dietary glycemic load in relation to risks of birth defects overall, and in particular, to risks of defects of the CNS, neural tube, cardiovascular system, GI tract, musculoskeletal system and urinary tract, using data collected in the Slone Epidemiology Center Birth Defects Study.
- NIH / NICHD (Principal Investigator)** 07/01/06-06/30/11
 Maternal Vasoactive Exposures and Risk of Clubfoot \$469,452
 This study's primary focus was to examine maternal use of vasoactive medications and cigarette smoking in relation to clubfoot risk, with particular attention to timing of exposure and phenotypes of affected children. This case-control study used population-based births and their mothers in North Carolina, Massachusetts, and New York State.
- NIH / NICHD (Principal Investigator)** 07/01/0-06/30/11
 Supplement to Maternal Vasoactive Exposures and Risk of Clubfoot \$77,729
 This supplemental grant supported genotyping of saliva samples collected in the parent study. The focus was on genes involved in xenobiotic metabolism.

- CDC (Principal Investigator)** 09/01/06-08/01/07
 Psycho-social Outcomes in Early-Elementary-School-Aged Children
 with Craniofacial Malformations \$100,000
 This project will measure quality of life, social adaptation, and behavioral problems in children born with and without oral clefts or craniosynostosis.
- NIH / NIDCR (Co-Investigator)** 12/01/06-11/30/07 (no cost extension to 7/31/2013)
 Craniofacial Microsomia and Genetic Variation in Hemostasis \$27,003
 This study addresses the vascular disruption hypothesis of craniofacial microsomia (also known as hemifacial microsomia) etiology by assessing variation in candidate genes involved in vasculogenesis and hemostasis. Dr. Jaqueline Starr at University of Washington, Seattle and Forsyth Institute, Boston is Principal Investigator.
- NIH / NIDCR (Principal Investigator)** 09/15/04-06/30
 Hemifacial Microsomia: Psychosocial and Other Sequelae \$415,932
 The major goal of this project was to conduct a large-scale follow-up study to evaluate the psychosocial, dental, orthodontic and medical sequelae among children born with this craniofacial malformation.
- BU Faculty Research Development Grant (Principal Investigator)** 2003
 Pilot study of Response Rates for Hemangioma Screening \$2,387
 This grant provided monetary incentives for a sample of Massachusetts mothers to determine whether response rates would be improved.
- NIH / NIDCR (Principal Investigator)** 7/1/97-12/31/02
 Case-Control Study of Hemifacial Microsomia and Drug Use \$368,729
 The major goals of this study were to examine a variety of maternal exposures in relation to the risks of hemifacial microsomia.
- NIH Fogarty Senior International Fellowship (Principal Investigator)** 3/1/01-8/31/01
 Medication Use and Birth Defects in Western Australia \$45,000
 This project examined vasoactive medication use and cigarette smoking in relation to birth defects that can arise from vascular disruption in the developing fetus.
- BU Faculty Research Development Grant (Principal Investigator)** 10/00-6/01
 Coding medications for the Western Australia Birth Defects Study \$11,891
 This grant supported research pharmacist time and materials to code medications reported in a case-control study of birth defects in Australia. The coding allowed analyses to be conducted according to pharmacologic action.
- Proctor&Gamble/MerrellDow/Wellcome (Principal Investigator)** 8/1/94-0/31/98
 Gastroschisis, Small Intestinal Defects, and Maternal
 Decongestant Use \$156,899
 The major goals of this project were to examine maternal uses of decongestants and other drugs in pregnancy in relation to the risks of two abdominal birth defects.
- NIH / NICHD (Co-Investigator)** 12/01/04-11/30/07
 Teratogenicity of Drugs Most Commonly Used in Pregnancy \$225,000

The goal of this project is to evaluate the safety of acetaminophen, aspirin, ibuprofen, and amoxicillin and their role in the etiology of human birth defects. Drs. Allen Mitchell and Sonia Hernandez-Diaz are Co-Principal Investigators.

NIH / NICHD (Co-Investigator) 4/1/98-3/31/03
 Risk Factors for Pulmonary Hypertension of the Newborn \$438,206
 This case-control study examined maternal medical and pharmaceutical risk factors for pulmonary hypertension of the newborn, using data collected by the Slone Epidemiology Center Birth Defects Study. Dr. Allen Mitchell is Principal Investigator.

NIH / NICHD (Co-Investigator) 8/1/00-7/31/05
 Pharmacogenetic Determinants of Human Birth Defects \$684,606
 This study assessed medications and metabolic factors in the etiology of human birth defects. Dr. Allen Mitchell is Principal Investigator.

PENDING:

R40 MCH / HRSA (Principal Investigator) 02/01/13-01/31/16
 Longitudinal study of gestational antidepressant and other exposures
 and neurobehavioral outcomes \$243,217
 This study is identify pregnancy predictors of adverse outcomes later in life so that preventative strategies can be employed. It will

PEER-REVIEWED PUBLICATIONS:

1. Werler MM, Pober BR, Holmes LB. Teratogen update: smoking and pregnancy. *Teratology* 1985;32:473-81.
2. Leppig KA, Werler MM, Cann CI, Cook CA, Holmes LB. Predictive value of minor anomalies: I. association with major malformations. *J Pediatr* 1987;110:530-7.
3. Louik C, Mitchell A, Werler M, Hanson J, Shapiro S. Maternal exposure to spermicides in relation to certain birth defects. *N Engl J Med* 1987;317:474-8.
4. Rosenberg L, Werler MM, Kaufman DW, Shapiro S. Coffee drinking and myocardial infarction in young women: an update. *Am J Epidemiol* 1987;126:147-9.
5. Werler MM, Pober BR, Nelson K, Holmes LB. Reporting accuracy among mothers of malformed and nonmalformed infants. *Am J Epidemiol* 1989;129:415-21.
6. Rosenberg L, Werler MM, Palmer JR, Kaufman DW, Warshauer ME, Stolley PD, Shapiro S. The risks of cancers of the colon and rectum in relation to coffee consumption. *Am J Epidemiol* 1989;130:895-903.

7. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. *N Engl J Med* 1989;321:1639-42.
8. Kaufman DW, Werler MM, Palmer JR, Rosenberg L, Stolley PD, Warshauer ME, Clarke EA, Miller DR, Shapiro S. Diazepam use in relation to breast cancer: results from two case-control studies. *Am J Epidemiol* 1990;131:483-90.
9. Werler MM, Pober BR, Nelson K, Holmes LB. Reporting accuracy among mothers of malformed and nonmalformed infants-reply [letter to the editor]. *Am J Epidemiol* 1990;131:937-8.
10. Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal vitamin A supplementation in relation to selected birth defects. *Teratology* 1990;42:497-503.
11. Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal cigarette smoking during pregnancy in relation to oral clefts. *Am J Epidemiol* 1990;132:926-32.
12. Shapiro S, Mitchell AA, Werler MM. Effect of multivitamin/folic acid supplements on the risk of neural tube defects [letter to the editor]. *J Am Med Assoc* 1990;263:2748.
13. Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal alcohol use in relation to selected birth defects. *Am J Epidemiol* 1991;134:691-8.
14. Werler MM, Mitchell AA, Shapiro S. Demographic, reproductive, medical, and environmental factors in relation to gastroschisis. *Teratology* 1992;45:353-60.
15. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. *Teratology* 1992;45:361-7.
16. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. *J Am Med Assoc* 1993;269:1257-61.
17. Werler MM, Mitchell AA. Case-control study of vitamin supplementation and neural tube defects: consideration of potential confounding by lifestyle factors. *Ann N Y Acad Sci* 1993;678:276-83.
18. Werler MM, Louik C, Shapiro S, Mitchell AA. Ovulation induction and risk of neural tube defects. *Lancet* 1994;344:445-6.
19. Werler MM, Mitchell AA. More on folic acid and neural tube defects [letter to the editor]. *Am J Public Health* 1995;85:269.
20. Werler MM, Lammer EJ, Mitchell AA. Teratogenicity of high vitamin A intake [letter to the editor]. *N Engl J Med* 1996;334:1195-6.
21. Werler MM, Louik C, Shapiro SS, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. *J Am Med Assoc* 1996;275:1089-92.

22. Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptual folic acid supplementation and oral clefts. *Am J Epidemiol* 1996;143:1229-34.
23. Werler MM, Cragan JD, Wasserman CR, Shaw GM, Erickson JD, Mitchell AA. Multivitamin supplementation and multiple births. *Am J Med Genet* 1997;71:93-6.
24. Werler MM. Teratogen update: smoking and reproductive outcomes. *Teratology* 1997;55:382-8.
25. Lief S, Olshan AF, Werler M, Savitz DA, Mitchell AA. Selection bias and the use of controls with malformations in case-control studies of birth defects. *Epidemiology* 1999;10:238-41.
26. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol* 1999;150:675-82.
27. Lief S, Olshan AF, Werler M, Strauss RP, Smith J, Mitchell A. Maternal cigarette smoking during pregnancy and risk of oral clefts in newborns. *Am J Epidemiol* 1999;150:683-94.
28. Werler MM, Louik C, Mitchell AA. Achieving a public health recommendation for preventing neural tube defects with folic acid. *Am J Public Health* 1999;89:1637-40.
29. Werler MM, Mitchell AA. Neural-tube defects [letter to the editor]. *N Engl J Med* 2000;342:1135-6.
30. Rao RS, Glynn RJ, Werler MM, Van Bennekom CM, Mitchell AA. Comparison of alternative survey methods for sensitive self-reported behaviours in a follow-up study of isotretinoin. *J Epidemiol Biostat* 2000;5:133-6.
31. Louik C, Frumkin H, Ellenbecker MJ, Goldman RH, Werler MM, Mitchell AA. Use of a job-exposure matrix to assess occupational exposures in relation to birth defects. *J Occup Environ Med* 2000;42:693-703.
32. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 2000;343:1608-14.
33. Werler MM. Medication use in pregnancy in the U.S. [abstract]. *Teratology* 2000;62:363.
34. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. *Am J Epidemiol* 2001;153:961-8.
35. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. *Am J Epidemiol* 2002;155:26-31.
36. Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. *Am J Epidemiol* 2002;155:176-84.

37. Werler MM. Exposure assessment in studies of oral clefts. In: Wyszynski DF, ed. *Cleft lip and palate: from origin to treatment*. New York: Oxford University Press, 2002:108-16.
38. Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. *Am J Obstet Gynecol* 2002;186:288-90.
39. Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. *Am J Epidemiol* 2002;156:806-12.
40. Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of maternal factors and amniotic band defects. *Birth Defects Res A Clin Mol Teratol* 2003;67:68-72.
41. Waller DK, Tita ATN, Werler MM, Mitchell AA. Association between pre-pregnancy maternal body mass index and the risk of having an infant with a congenital diaphragmatic hernia. *Birth Defects Res A Clin Mol Teratol* 2003;67:73-6.
42. Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. *Epidemiology* 2003;14:349-54.
43. Meyer KA, Werler MM, Hayes C, Mitchell AA. Low maternal alcohol consumption during pregnancy and oral clefts in offspring: the Slone Birth Defects Study. *Birth Defects Res A Clin Mol Teratol* 2003;67:509-14.
44. Werler MM. Environmental factors and vascular disruption defects. *Proceedings of 14th Fukuoka International Symposium of Perinatal Medicine*. Fukuoka, Japan: Kyushu University, September 6-7, 2003:26-30.
45. Hernández-Díaz S, Hernán MA, Meyer K, Werler MM, Mitchell AA. Case-crossover and case-time-control designs in birth defects epidemiology. *Am J Epidemiol* 2003;158:385-91.
46. Werler MM, Bower C, Payne J, Serna P. Findings on potential teratogens from a case-control study in Western Australia. *Aust N Z J Obstet Gynaecol* 2003;43(6):443-7.
47. Werler MM, Sheehan JE, Hayes C, Padwa BL, Mitchell AA, Mulliken JB. Demographic and reproductive factors associated with hemifacial microsomia. *Cleft Palate Craniofac J* 2004;41:494-500.
48. Werler MM, Sheehan JE, Hayes C, Mitchell AA, Mulliken JB. Vasoactive exposures, vascular events, and hemifacial microsomia. *Birth Defects Res A Clin Mol Teratol* 2004;70(6):389-95.
49. de Jong-van den Berg LTW, Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Trends and predictors of folic acid awareness and periconceptional use in pregnant women. *Am J Obstet Gynecol* 2005;192:121-8.
50. Cleves MA, Savell VH, Raj S, Zhao W, Correa A, Werler MM, Hobbs CA, and the National Birth Defects Prevention Study. Maternal use of acetaminophen and nonsteroidal

anti-inflammatory drugs (NSAIDS), and muscular ventricular septal defects. *Birth Defects Res A Clin Mol Teratol* 2004;70:107-13.

51. Werler MM, McCloskey C, Edmonds LD, Olney R, Honein MA, Reefhuis J, and the National Birth Defects Prevention Study. Evaluation of an association between loratadine and hypospadias--United States, 1997-2001. *MMWR* 2004;53(10):219-21.
52. Anderson JL, Waller DK, Canfield MA, Shaw GM, Watkins ML, Werler MM. Maternal obesity, gestational diabetes, and central nervous system birth defects. *Epidemiology* 2005;16(1):87-92.
53. Werler MM, Sheehan JE, Mitchell AA. Gulf war veterans and hemifacial microsomia. *Birth Defects Res A Clin Mol Teratol* 2005;73:50-2.
54. Hernández-Díaz S, Wu XF, Hayes C, Werler MW, Ashok TDS, Badovinac R, Kelsey KT, Mitchell AA. Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. *Epidemiology* 2005;16(5):628-34.
55. Werler MM, Mitchell AA, Hernández-Díaz S, Honein MA, and the National Birth Defects Prevention Study. Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol* 2005;193:771-7.
56. Chambers CD, Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006;354(6):579-87.
57. Siega-Riz AM, Olshan AF, Werler MM, Moore C and the National Birth Defects Prevention Study. Fat intake and the risk of gastroschisis. *Birth Defects Res A Clin Mol Teratol* 2006;76(4):241-5.
58. Louik C, Hernández-Díaz S, Werler MM, Mitchell AA. Nausea and vomiting in pregnancy: maternal characteristics and risk factors. *Paediatr Perinat Epidemiol* 2006;20:270-8.
59. Edwards EM, Werler MM. Alcohol consumption and time to recognition of pregnancy. *Matern Child Health J* 2006;10(6):467-72.
60. Werler MM. Teratogen update: pseudoephedrine. *Birth Defects Res A Clin Mol Teratol* 2006;76(6):445-52.
61. Meijer WM, Werler MM, Louik C, Hernández-Díaz S, de Jong-van den Berg LTW, Mitchell AA. Can folic acid protect against congenital heart defects in Down syndrome? *Birth Defects Res A Clin Mol Teratol* 2006;76(10):714-7.
62. Badovinac RL, Werler MM, Williams PL, Kelsey KT, Hayes C. Folic acid-containing supplement consumption during pregnancy and risk for oral clefts: a meta-analysis. *Birth Defects Res A Clin Mol Teratol* 2007;79:8-15.

63. Kabali C, Werler MM. Pre-pregnant body mass index, weight gain and the risk of delivering large babies among non-diabetic mothers. *Int J Gynaecol Obstet* 2007;97:100-4.
64. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *N Engl J Med* 2007;356:2675-83.
65. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. *Pediatrics* 2007;120(2):272-82.
66. Hernández-Díaz S, Werler MM, Mitchell AA. Gestational hypertension in pregnancies supported by infertility treatments: role of infertility, treatments, and multiple gestations. *Fertil Steril* 2007;88(2):438-45. PMID:PMC2696199.
67. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ, and the National Birth Defects Prevention Study. Maternal corticosteroid use and orofacial clefts. *Am J Obstet Gynecol* 2007;197(6):585.e1-7. doi: 10.1016/j.ajog.2007.05.046.
68. Caton AR, Bell EM, Druschel CM, Werler MM, Mitchell AA, Browne ML, McNutt LA, Romitti PA, Olney RS, Correa A, and the National Birth Defects Prevention Study. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. *Birth Defects Res A Clin Mol Teratol* 2008;82(1):34-40.
69. Carter TC, Druschel CM, Romitti PA, Bell EM, Werler MM, Mitchell AA, and the National Birth Defects Prevention Study. Antifungal drugs and the risk of selected birth defects. *Am J Obstet Gynecol* 2008;198:191.e1-7. doi: 10.1016/j.ajog.2007.08.044.
70. Toh S, Mitchell AA, Werler MM, Hernández-Díaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. *Am J Epidemiol* 2008;167(6):633-40. doi: 10.1093/aje/kwm367.
71. Bitsko RH, Reefhuis J, Louik C, Werler MM, Feldkamp ML, Waller DK, Frias J, Honein MA, and the National Birth Defects Prevention Study. Periconceptional use of weight loss products including Ephedra and the association with birth defects. *Birth Defects Res A Clin Mol Teratol* 2008;82(8):553-62.
72. Nelson JW, Werler MM. Socioeconomic status as a modifier of the relationship between antibiotic use during pregnancy and birthweight. *Birth* 2008;35(3):196-203. doi: 10.1111/j.1523-536X.2008.00240.x.
73. Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA, and the National Birth Defects Prevention Study. Maternal exposure to statins and risk for birth defects: a case-series approach [research letter]. *Am J Med Genet A* 2008;146A(20):2701-5. doi: 10.1002/ajmg.a.32493.
74. van Gelder M, Reefhuis J, Caton A, Werler MM, Druschel C, Roeleveld N, and the National Birth Defects Prevention Study. Maternal periconceptional illicit drug use and the risk of

congenital malformations. *Epidemiology* 2009;20(1):60-6. doi: 10.1097/EDE.0b013e31818e5930.

75. Mosley BS, Cleves MA, Siega-Riz AM, Shaw GM, Canfield MA, Waller DK, Werler MM, Hobbs CA, and the National Birth Defects Prevention Study. Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the United States. *Am J Epidemiol* 2009;169(1):9-17. doi: 10.1093/aje/kwn331.
76. Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A, and the National Birth Defects Prevention Study. Use of antihistamine medications during early pregnancy and isolated major malformations. *Birth Defects Res A Clin Mol Teratol* 2009;85(2):137-50. doi: 10.1002/bdra.20513.
77. Werler MM, Bosco JLF, Shapira SK, and the National Birth Defects Prevention Study. Maternal vasoactive exposures, amniotic bands, and terminal transverse limb defects. *Birth Defects Res A Clin Mol Teratol* 2009;85:52-7. doi: 10.1002/bdra.20524. PMID: PMC2741326.
78. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernández-Díaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. *Am J Psychiatry* 2009;166:320-8. doi: 10.1176/appi.ajp.2008.08060817. PMID: PMC2735348.
79. Werler MM, Starr JR, Cloonan YK, Speltz ML. Hemifacial microsomia: from gestation to childhood. *J Craniofac Surg* 2009;20(Suppl. 1):664-9. PMID: PMC2791372.
80. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, McNutt LA, Romitti PA, Mitchell AA, Olney RS, Correa A, and the National Birth Defects Prevention Study. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. *Hypertension* 2009;54(1):63-70. doi: 10.1161/HYPERTENSIONAHA.109.129098.
81. Werler MM, Mitchell AA, Moore CA, Honein MA, and the National Birth Defects Prevention Study. Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis?. *Am J Med Genet* 2009;149A(7):1399-406. doi: 10.1002/ajmg.a.32897. PMID: PMC2739090.
82. Li L, Werler MM. Fruit and vegetable intake and risk of upper respiratory tract infection in pregnant women. *Public Health Nutr* 2009;13(2):276-82. doi: 10.1017/S1368980009990590. PMID: PMC2808435.
83. Cloonan YK, Kifle Y, Davis S, Speltz ML, Werler MM, Starr JR. Sleep outcomes in children with hemifacial microsomia and controls: a follow-up study. *Pediatrics* 2009;124(2):e313-21. doi: 10.1542/peds.2008-3488. PMID: PMC2739665.
84. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernández-Díaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. *J Clin*

- Psychopharmacol 2009;29(6):555-60. doi: 10.1097/JCP.0b013e3181bf344c. PMID: PMC3206605.
85. Carmichael SL, Ma C, Werler MM, Olney RS, Shaw GM, and the National Birth Defects Prevention Study. Maternal corticosteroid use and hypospadias. *J Pediatr* 2009;155(1):39-44.e1. doi: 10.1016/j.jpeds.2009.01.039. PMID: PMC2764545.
 86. Yazdy MM, Liu S, Mitchell AA, Werler MM. Maternal dietary glyceimic intake and the risk of neural tube defects. *Am J Epidemiol* 2010;171(4):407-14. doi: 10.1093/aje/kwp395. PMID: PMC2842193.
 87. Hobbs CA, Shaw GM, Werler MM, Mosley B. Folate status and birth defect risk: epidemiological perspective. In: Bailey LB, ed. *Folate in health and disease*. 2nd ed. Boca Raton, FL: CRC Press, 2009:133-54.
 88. Werler MM. Hypothesis: could Epstein-Barr virus play a role in the development of gastroschisis? *Birth Defects Res A Clin Mol Teratol* 2010;88(2):71-5. doi: 10.1002/bdra.20640.
 89. Burris HH, Mitchell AA, Werler MM. Periconceptional multivitamin use and its association with infant birth weight disparities. *Ann Epidemiol* 2010;20:233-40. doi: 10.1016/j.annepidem.2009.12.003.
 90. van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N, and the National Birth Defects Prevention Study. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. *Drug Alcohol Depend* 2010;109:243-7. doi: 10.1016/j.drugalcdep.2010.01.007.
 91. Werler MM. Birth defects. In: Buck-Louis GM, Platt RW, eds. *Reproductive and perinatal epidemiology*. New York: Oxford University Press, 2011:186-203.
 92. Burris HH, Werler MM. U.S. provider reported folic acid or multivitamin ordering for non-pregnant women of childbearing age: NAMCS and NHAMCS, 2005-2006. *Matern Child Health J* 2011;15(3):352-9. doi: 10.1007/s10995-010-0587-6.
 93. Collett BR, Speltz ML, Cloonan YK, Leroux BG, Kelly JP, Werler MM. Neurodevelopmental outcomes in children with hemifacial microsomia. *Arch Pediatr Adolesc Med* 2011;165(2):134-40. PMID: PMC3142696.
 94. Hernandez RK, Mitchell AA, Werler MM. Decongestant use during pregnancy and its association with preterm delivery. *Birth Defects Res A Clin Mol Teratol* 2010;88:715-21.
 95. Louik C, Schatz M, Hernández-Díaz S, Werler MM, Mitchell AA. Asthma in pregnancy and its pharmacologic treatment. *Ann Allergy Asthma Immunol* 2010;105:110-7. PMID: PMC2953247.

96. Al-Farsi YM, Brooks DR, Werler MM, Cabral HJ, Wallenburg HC, Al-Shafei MA. Effect of high parity on the occurrence of pre-diabetes: a cohort study. *Acta Obstet Gynecol Scand* 2010;89(9):1182-6.
97. Al-Farsi YM, Brooks DR, Werler MM, Cabral HJ, Al-Shafei MA, Wallenburg HC. Effect of high parity on occurrence of anemia in pregnancy: a cohort study. *BMC Pregnancy Childbirth* 2011;11(1):7. doi: 10.1186/1471-2393-11-7.
98. Collett BR, Cloonan YK, Speltz ML, Anderka M, Werler MM. Psychosocial functioning in children with and without orofacial clefts and their parents. *Cleft Palate Craniofac J* 2012;49(4):397-405. doi: 10.1597/10-007.
99. Dufton L, Speltz ML, Kelly JP, Leroux B, Collett BR, Werler MM. Psychosocial outcomes in children with hemifacial microsomia. *J Pediatr Psychol* 2011;36(7):794-805. doi: 10.1093/jpepsy/jsq112. PMID: PMC3146752.
100. Brender JD, Kelley KE, Werler MM, Langlois PH, Suarez L, Canfield MA, and the National Birth Defects Prevention Study. Prevalence and patterns of nitrosatable drug use among U.S. women during early pregnancy. *Birth Defects Res A Clin Mol Teratol* 2011;91:258-64.
101. Yazdy MM, Mitchell AA, Liu S, Werler MM. Maternal dietary glycaemic intake during pregnancy and the risk of birth defects. *Paediatr Perinat Epidemiol* 2011;25:340-6. doi:10.1111/j.1365-3016.2011.01198.x. PMID: PMC3474333.
102. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, and the National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. *Am J Obstet Gynecol* 2011;205:51.e1-8. doi: 10.1016/j.ajog.2011.02.029. PMID: PMC3793635.
103. Ahrens K, Yazdy M, Mitchell AA, Werler MM. Folic acid intake and spina bifida in the era of dietary folic acid fortification. *Epidemiology* 2011;22(5):731-7. doi: 10.1097/EDE.0b013e3182227887.
104. Werler MM, Louik C, Mitchell AA. Case-control studies for identifying novel teratogens. *Am J Med Genet C Semin Med Genet* 2011;157:201-8. doi: 10.1002/ajmg.c.30307. PMID: PMC3483035.
105. Gilboa S, Broussard C, Devine O, Duwe K, Flak A, Boulet S, Moore C, Werler MM, Honein M. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. *Am J Med Genet C Semin Med Genet* 2011;157:234-46. doi: 10.1002/ajmg.c.30306.
106. Barger MK, Weiss J, Nannini A, Werler MM, Heeren T, Stubblefield PG. Risk factors for uterine rupture among women who attempt a vaginal birth after a previous Cesarean: a case-control study. *J Reprod Med* 2011;56(7-8):313-20.

107. Yau WP, Lin KJ, Werler MM, Louik C, Mitchell AA, Hernández-Díaz S. Drug certainty-response in interview-based studies. *Pharmacoepidemiol Drug Saf* 2011;20:1210-6. doi: 10.1002/pds.2234. PMID: PMC3222943.
108. Werler MM, Ahrens KA, Bosco JLF, Mitchell AA, Anderka MT, Gilboa SM, Holmes LB, and the National Birth Defects Prevention Study. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. *Ann Epidemiol* 2011;21:842-50. doi: 10.1016/j.annepidem.2011.08.002.
109. Brender JD, Werler MM, Kelley KE, Vuong AM, Shinde MU, Zheng Q, Huber JC, Sharkey JR, Griesenbeck JS, Romitti PA, Langlois PH, Suarez L, Canfield MA, and the National Birth Defects Prevention Study. Nitrosatable drug exposure during early pregnancy and neural tube defects in offspring. *Am J Epidemiol* 2011;174(11):1286-95. doi: 10.1093/aje/kwr254.
110. Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Díaz S, Rasmussen SA, and the National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol* 2012;94(1):22-30. doi: 10.1002/bdra.22865. PMID: PMC3299087.
111. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M, and the National Birth Defects Prevention Study. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. *Am J Obstet Gynecol* 2012;206(3):228.e1-8. doi: 10.1016/j.ajog.2011.11.019.
112. Barger MK, Nannini A, Weiss J, Declercq ER, Stubblefield P, Werler MM, Ringer S. Severe maternal and perinatal outcomes from uterine rupture among women at term with a trial of labor. *J Perinatol* 2012;32(11):837-43. doi: 10.1038/jp.2012.2.
113. Yazdy MM, Tinker SC, Mitchell AA, Demmer LA, Werler MM. Maternal tea consumption during early pregnancy and the risk of spina bifida. *Birth Defects Res A Clin Mol Teratol* 2012;94(10):756-61. doi: 10.1002/bdra.23025.
114. Al-Farsi YM, Brooks DR, Werler MM, Cabral HJ, Al-Shafei MA, Wallenburg HC. Effect of high parity on occurrence of some fetal growth indices: a cohort study. *Int J Womens Health* 2012;4:289-93.
115. Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, Hernández-Díaz S, and the National Birth Defects Prevention Study. Use of topiramate in pregnancy and risk of oral clefts. *Am J Obstet Gynecol* 2012;207(5):405.e1-7. doi: 10.1016/j.ajog.2012.07.008. PMID: PMC3484193.
116. Brender JD, Werler MM, Shinde MU, Vuong AM, Kelley KE, Huber Jr JC, Sharkey JR, Griesenbeck JS, Romitti PA, Malik S, Suarez L, Langlois PH, Canfield MA, and the National Birth Defects Prevention Study. Nitrosatable drug exposure during the first trimester of pregnancy and selected congenital malformations. *Birth Defects Res A Clin Mol Teratol* 2012;94:701-13. doi: 10.1002/bdra.23060.

117. Getz KD, Anderka MT, Werler MM, Case AP. Short interpregnancy interval and gastroschisis risk in the National Birth Defects Prevention Study. *Birth Defects Res A Clin Mol Teratol* 2012;94:714-20. doi: 10.1002/bdra.23061.
118. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. *Ann Epidemiol* 2012;22:799-806. doi: 10.1016/j.annepidem.2012.09.003. PMID: PMC3489973.
119. Parker SE, Werler MM, Shaw GM, Anderka M, Yazdy MM, and the National Birth Defects Prevention Study. Dietary glycemic index and the risk of birth defects. *Am J Epidemiol* 2012;176(12):1110–20. doi: 10.1093/aje/kws201.
120. Cloonan YK, Collett B, Speltz ML, Anderka A, Werler MM. Psychosocial outcomes in children with and without non-syndromic craniosynostosis: findings from two studies. *Cleft Palate Craniofac J* 2013;50(4):406-13. doi: 10.1597/11-074.
121. Radin RG, Mitchell AA, Werler MM. Predictors of recall certainty of dates of analgesic medication use in pregnancy. *Pharmacoepidemiol Drug Saf* 2013;22:25-32. doi: 10.1002/pds.3300. PMID: PMC3443548.
122. Van Bennekom CM, Mitchell AA, Moore CA, Werler MM, and the National Birth Defects Prevention Study. Vasoactive exposures during pregnancy and risk of microtia. *Birth Defects Res A Clin Mol Teratol* 2013;97(1):53-9. doi: 10.1002/bdra.23101.
123. Van Marter LJ, Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. *Pediatrics* 2013;131:79-87. doi: 10.1542/peds.2012-0496. PMID: PMC3529942.
124. Lind JN, Tinker SC, Broussard CS, Reefhuis J, Carmichael SL, Honein MA, Olney RS, Parker SE, Werler MM, and the National Birth Defects Prevention Study. Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. *Pharmacoepidemiol Drug Saf* 2013;22(7):783-93. doi: 10.1002/pds.3448.
125. Tinker SC, Gibbs C, Devine O, Crider K, Werler MM, Anderka M, Reefhuis J, and the National Birth Defects Prevention Study. Impact of time to maternal interview on interview responses in the National Birth Defects Prevention Study. *Am J Epidemiol* 2013;177(11):1225-35. doi: 10.1093/aje/kws352.
126. Werler MM, Yazdy MM, Mitchell AA, Meyer RE, Druschel CM, Anderka M, Kasser JR, Mahan ST. Descriptive epidemiology of idiopathic clubfoot. *Am J Med Genet A* 2013;161(7):1569-78. doi: 10.1002/ajmg.a.35955. PMID: PMC3689855.
127. Parker SE, Yazdy MM, Tinker SC, Mitchell AA, Werler MM. The impact of folic acid intake on the association between diabetes, obesity, and spina bifida. *Am J Obstet Gynecol* 2013;209(3):239.e1-8. doi: 10.1016/j.ajog.2013.05.047.

128. Shinde MU, Vuong AM, Brender JD, Werler MM, Kelley KE, Huber JC, Sharkey JR, Zheng Q, Suarez L, Langlois PH, Canfield MA, Romitti PA, Malik S, and the National Birth Defects Prevention Study. Prenatal exposure to nitrosatable drugs, vitamin C, and risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol* 2013;97(8):515-31. doi: 10.1002/bdra.23137.
129. Brender JD, Weyer PJ, Romitti PA, Mohanty BP, Shinde MU, Vuong AM, Sharkey JR, Dwivedi D, Horel SA, Kantamneni J, Huber Jr JC, Zheng Q, Werler MM, Kelley KE, Griesenbeck JS, Zhan FB, Langlois PH, Suarez L, Canfield MA, and the National Birth Defects Prevention Study. Prenatal nitrate intake from drinking water and selected birth defects in offspring of participants in the National Birth Defects Prevention Study. *Environ Health Perspect* 2013;121(9):1083-9. doi: 10.1289/ehp.1206249.
130. Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM, and the National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. *Paediatr Perinat Epidemiol* 2013;27(4):340-5. doi: 10.1111/ppe.12064. PMID: PMC3690801.
131. Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernández-Díaz S. Use of decongestants during pregnancy and the risk of birth defects. *Am J Epidemiol* 2013;178(2):198-208. doi: 10.1093/aje/kws427. PMID: PMC3816336.
132. Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Risk of spina bifida and maternal cigarette, alcohol, and coffee use during the first month of pregnancy. *Int J Environ Res Public Health* 2013;10:3263-81. doi: 10.3390/ijerph10083263.
133. Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. *Obstet Gynecol* 2013;122(4):838-44. doi: 10.1097/AOG.0b013e3182a6643c.
134. Stone SL, Speltz ML, Collett B, Werler MM. Socioeconomic factors in relation to discrepancy in parent versus teacher ratings of child behavior. *J Psychopathol Behav Assess* 2013;35(3):314-20. doi: 10.1007/s10862-013-9348-3. PMID: PMC3772786.
135. Li Q, Mitchell AA, Werler MM, Yau WP, Hernández-Díaz S. Assessment of antihistamine use in early pregnancy and birth defects. *J Allergy Clin Immunol Pract* 2013;1(6):666-74.e1. doi: 10.1016/j.jaip.2013.07.008. PMID: PMC4140658.
136. Mahan ST, Yazdy MM, Kasser JR, Werler MM. Is it worthwhile to routinely ultrasound screen children with idiopathic clubfoot for hip dysplasia? *J Pediatr Orthop* 2013;33(8):847-51. doi: 10.1097/BPO.000000000000100. PMID: PMC4574100.
137. Caspers KM, Romitti PA, Lin S, Olney RS, Holmes LB, Werler MM, and the National Birth Defects Prevention Study. Maternal periconceptional exposure to cigarette smoking and congenital limb deficiencies. *Paediatr Perinat Epidemiol* 2013;27(6):509-20. doi: 10.1111/ppe.12075.

138. Khetani MA, Collett B, Speltz ML, Werler MM. Health-related quality of life in children with hemifacial microsomia: parent and child perspectives. *J Dev Behav Pediatr* 2013;34(9):661-8. doi: 10.1097/DBP.0000000000000006. PMID: PMC4218728.
139. Parker SE, Yazdy MM, Mitchell AA, Demmer LA, Werler MM. A description of spina bifida cases and co-occurring malformations, 1976-2011. *Am J Med Genet* 2014;164(2):432-40. doi: 10.1002/ajmg.a.36324. PMID: PMC4353584.
140. Van Zutphen AR, Werler MM, Browne MM, Romitti PA, Bell EM, McNutt LA, Druschel CM, Mitchell AA, and the National Birth Defects Prevention Study. Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. *Obstet Gynecol* 2014;123(2):309-17. doi: 10.1097/AOG.0000000000000103.
141. Mahan ST, Yazdy MM, Kasser JR, Werler MM. Prenatal screening for clubfoot: what factors predict prenatal detection? *Prenat Diagn* 2014;34(4):389-93. doi: 10.1002/pd.4320. PMID: PMC4028147.
142. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM, Shaw GM, Carmichael SL. Corticosteroid use and risk of orofacial clefts. *Birth Defects Res A Clin Mol Teratol* 2014;100(6):499-506. doi: 10.1002/bdra.23248.
143. Werler MM, Yazdy MM, Kasser JR, Mahan ST, Meyer RE, Anderka M, Druschel CM, Mitchell AA. Medication use in pregnancy in relation to the risk of isolated clubfoot in offspring. *Am J Epidemiol* 2014;180(1):86-93. doi: 10.1093/aje/kwu096. PMID: PMC4133556.
144. Parker SE, Werler MM. Epidemiology of ischemic placental disease: a focus on preterm gestations. *Semin Perinatol* 2014;38(3):133-8. doi: 10.1053/j.semperi.2014.03.004.
145. Yazdy MM, Mitchell AA, Werler MM. Maternal genitourinary infections and the risk of gastroschisis [editor's choice]. *Am J Epidemiol* 2014;180(5):518-25. doi: 10.1093/aje/kwu157. PMID: PMC4143079.
146. Yazdy MM, Mitchell AA, Louik C, Werler MM. Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot. *Epidemiology* 2014;25(6):859-65. doi: 10.1097/EDE.0000000000000157. PMID: PMC4180776.
147. Ahrens KA, Louik C, Kerr S, Mitchell AA, Werler MM. Seasonal influenza vaccination during pregnancy and the risks of preterm delivery and small-for-gestational age birth. *Paediatr Perinat Epidemiol* 2014;28(6):498-509. doi: 10.1111/ppe.12152. PMID: PMC Journal – In Process.
148. Parker SE, Starr JR, Collett BR, Speltz ML, Werler MM. Nausea and vomiting during pregnancy and neurodevelopmental outcomes in offspring. *Paediatr Perinat Epidemiol* 2014;28(6):527-35. doi: 10.1111/ppe.12151. PMID: PMC4232991.

149. van Gelder MM, Van Bennekom CM, Louik C, Werler MM, Roeleveld N, Mitchell AA. Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study. *Br J Obstet Gynaecol* 2015;122:1002-9. doi: 10.1111/1471-0528.13138.
150. Werler MM, Yazdy MM, Kasser JR, Mahan ST, Meyer RE, Anderka M, Druschel CM, Mitchell AA. Maternal cigarette, alcohol, and coffee consumption in relation to risk of clubfoot. *Paediatr Perinat Epidemiol* 2015;29(1):3-10. doi: 10.1111/ppe.12163. PMID: PMC Journal – In Process.
151. Vuong AM, Shinde MU, Brender JD, Shipp EM, Huber Jr JC, Zheng Q, McDonald TJ, Sharkey JR, Hoyt AT, Werler MM, Kelley KE, Langlois PH, Canfield MA, and the National Birth Defects Prevention Study. Nitrosatable drug exposure during pregnancy and preterm and small-for-gestational-age births. *Paediatr Perinat Epidemiol* 2015;29(1):60-71. doi: 10.1111/ppe.12169.
152. Yazdy MM, Werler MM, Langlois PH, Anderka M, Vieira VM. Spatial analysis of gastroschisis in Massachusetts and Texas. *Ann Epidemiol* 2015;25(1):7-14. doi: 10.1016/j.annepidem.2014.10.001.
153. Parker SE, Werler MM, Gissler M, Tikkanen M, Ananth CV. Placental abruption and subsequent risk of pre-eclampsia: a population-based case-control study. *Paediatr Perinat Epidemiol* 2015;29(3): 211-9. doi: 10.1111/ppe.12184.
154. Parker SE, Jick SS, Werler MM. Intrauterine device use and the risk of pre-eclampsia: a case-control study. *BJOG* 2015. doi: 10.1111/1471-0528.13413 (epub ahead of print).
155. Yazdy MM, Werler MM, Feldkamp ML, Shaw GM, Mosley BS, Vieirae VM, and the National Birth Defects Prevention Study. Spatial analysis of gastroschisis in the National Birth Defects Prevention Study. *Birth Defects Res A Clin Mol Teratol* 2015;103(6):544-53. doi: 10.1002/bdra.23375. PMID: PMC4478213.
156. Yazdy MM, Mitchell AA, Louik C, Werler MM. The authors respond [letter to the editor]. *Epidemiology* 2015;26(3):e35-6. doi: 10.1097/EDE.0000000000000281. PMID: PMC4388046.
157. Werler MM, Parker SE. Bias from conditioning on live-births in pregnancy cohorts: an illustration based on neurodevelopment in children after prenatal exposure to organic pollutants (Liew et al. 2015) [letter to the editor]. *Int J Epidemiol* 2015. doi: 10.1093/ije/dyv139 (epub ahead of print).
158. Louik C, Werler MM, Anderka M, Mitchell AA. Application of data screening to drug exposure in large risk factor studies of birth defects. *Birth Defects Res A Clin Mol Teratol* 2015;103(8):713-7. doi: 10.1002/bdra.23407.

159. Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Impact of periconceptional use of nitrosatable drugs on the risk of neural tube defects. *Am J Epidemiol* 2015. doi: 10.1093/aje/kwv126 (epub ahead of print).
160. Yazdy MM, Werler MM. Comparison of web versus interview participants in a case-control study. *Ann Epidemiol* 2015;25(10):794-6. doi: 10.1016/j.annepidem.2015.07.007. PMID: PMC4567897.
161. Parker SE, Gissler M, Ananth CV, Werler MM. Induced abortions and the risk of preeclampsia among nulliparous women. *Am J Epidemiol* 2015;182(8):663-9. doi: 10.1093/aje/kwv184.
162. Parker SE, Gissler M, Ananth CV, Werler MM. Parker et al. respond to "Preeclampsia risk after induced abortion." *Am J Epidemiol* 2015;182(8):673-4. doi: 10.1093/aje/kwv183.
163. Benedum CM, Yazdy MM, Parker SE, Mitchell AA, Werler MM. Association of clomiphene and assisted reproductive technologies on the risk for neural tube defects. *Am J Epidemiol* 2015;182(8):675-84. doi: 10.1093/aje/kwv126.
164. Vuongan A, Kelley KE, Werler MM. Prenatal exposure to nitrosatable drugs, dietary intake of nitrites, and preterm births. *Am J Epidemiol* (in press).

EDITORIALS/COMMENTARIES:

165. Mitchell AA, Werler MM, Shapiro S. Analyses and reanalyses of epidemiologic data: learning lessons and maintaining perspective [commentary]. *Teratology* 1992;46:209-11.
166. Mitchell AA, Werler MM, Shapiro S. Response to the commentary "Should we consider a subject's knowledge of the etiologic hypothesis in the analysis of case-control studies?" [commentary]. *Am J Epidemiol* 1995;141:297-8.
167. Werler MM. Additional insights into the etiology of cardiac anomalies [editorial]. *Epidemiology* 2001;12:482-4.
168. Bower C, Werler MM. Folate before pregnancy: are we doing enough? [editorial]. *Med J Aust* 2001;174:619-20.
169. Werler MM. Maternal smoking and undescended testes: reaching a tipping point [commentary]. *Epidemiology* 2007;18:197-8.
170. Toh S, Mitchell AA, Werler MM, Hernández-Díaz S. Toh et al. respond to "Compromise or compromising?" [commentary]. *Am J Epidemiol* 2008;167(6):644-5. doi: 10.1093/aje/kwm369.
171. MacLehose RF, Werler MM. Importance of bias analysis in epidemiologic research [commentary]. *Paediatr Perinat Epidemiol* 2014;28(5):353-5. doi: 10.1111/ppe.12147.

172. Werler MM, Hernandez-Diaz S. Society for pediatric and perinatal epidemiologic research annual meeting: looking back, looking forward. *Paediatr Perinat Epidemiol* 2014;28(5):359-61. doi: 10.1111/ppe.12143.
173. Werler MM. Congenital malformations and consequential epidemiology. *Curr Epidemiol Rep* 2015;2(1):8-12.

BOOK CHAPTERS:

174. Werler MM, Pober BR, Holmes LB. Smoking and Pregnancy. In Sever JL and Brent RL, eds. *Teratogen Update: Environmentally Induced Birth Defect Risks*. New York: Alan R. Liss, Inc., 1986; 131-139.
175. Case-Control Study of Vitamin Supplementation and Neural Tube Defects: Consideration of Potential Confounding by Lifestyle Factors. In Keen CL, Bendich A, Whilite CC, eds. *Maternal Nutrition and Pregnancy Outcome*. New York: Annals of the New York Academy of Sciences, 1993; 276-283.
176. Werler MM. Chapter 10: Exposure assessment in studies of oral clefts. In: Wyszynski DF, ed. *Cleft Lip and Palate: From Origin to Treatment*. New York: Oxford University Press, 2002; 108-116.
177. Werler MM. Birth defects. In: Buck-Louis GM, Platt RW, eds. *Reproductive and Perinatal Epidemiology*. New York: Oxford University Press, 2011:186-203.

PAPERS IN PROGRESS:

1. Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Infertility Treatments and Risk of Neural Tube Defects
2. Werler MM. Timing of smoking and alcohol intake during pregnancy in relation to risk of clubfoot.
3. Werler MM, Yazdy MM, Hecht JT. Polymorphisms of xenobiotic metabolizer genes, cigarette smoking, and clubfoot risk.

INVITED PRESENTATIONS:

1. Training Epidemiologists: Looking to the Future. Society for Epidemiologic Research Plenary session. June 19, 2013, Boston, MA.

2. Interview Study on Pregnancy and Clubfoot. Massachusetts Center for Birth Defects Prevention. April 17, 2013, Boston, MA.
3. Anti-herpetic Medication Use and Gastroschisis. National Birth Defects Prevention Network, Atlanta, GA, February, 26 2013.
4. Case-Control Studies: Design & Issues. Teratology Society Education Course. June 2011, San Diego, CA.
5. Challenges in Exposure Measurement. Teratology Society San Diego, CA, June 26, 2011.
6. The Promise of Birth Defects Prevention. Congressional briefing on “Healthy Beginnings,” Capitol Hill, Washington DC, March 3, 2011.
7. Interview Study on Clubfoot. NICHD 5th Structural Birth Defects Meeting. May 8, 2007, Linthicum Heights, MD.
8. Interview Study on Clubfoot. NICHD 7th Structural Birth Defects Meeting November 10, 2009, Bethesda, MD.
9. Could Being Born with a Hole in the Abdominal Wall Result from Epstein Barr Virus? University of Minnesota Seminar Series, October 25, 2010, Minneapolis, Minn.
10. Medications and Pregnancy. 2010 Texas Birth Defects Research Symposium. October, 2010, Austin, Texas.
11. Improving retrospective ascertainment of medication exposures during pregnancy. Overcoming methodological challenges in identifying causes of birth defects. Society for Epidemiologic Research, June 21, 2007, Boston, MA
12. Vasoactive Compounds. Harvard Medical School Human Teratogens Course. April 29, 2003; April 27, 2004; May 24, 2005; April 24, 2007; April 18, 2009; April 28, 2011; April 23, 2013, Boston, MA.
13. When Public Health Succeeds, What Can Epidemiology Contribute? The Case of Folic Acid and Neural Tube Defects. Fifth Annual Summer Institute in Reproductive & Perinatal Epidemiology, July 23, 2008, Burlington, Vermont.
14. Vascular Disruption Defects: Epidemiologic Findings. Teratology Society Annual Meeting. July 2, 2008, Monterey, CA.
15. Hypothesis: Could EBV play a role in the development of gastroschisis? Slone Epidemiology Center Brown Bag Series. May 20, 2010, Boston, MA.
16. Hemifacial Microsomia: From Gestation to Childhood. Dr. John Mulliken Festschrift. April 23, 2008. Boston MA.
17. Epidemiologic and Genetic Studies of A Not Uncommon Craniofacial Malformation –

Hemifacial Microsomia. New England Medical Center Clinical Genetics Rounds, 2007, Boston, MA.

18. What is Amniotic Rupture Sequence? National Birth Defects Prevention Study annual meeting. November 16, 2006, Atlanta, GA.
19. Quality Reviews of NIH Study Sections. American College of Epidemiology workshop. June 24, 2006, Seattle, WA.
20. Primary Prevention of Birth Defects. National Birth Defects Prevention Network. January 30, 2006, Arlington, VA.
21. Over-the-Counter Medication Use in the National Birth Defects Prevention Study. National Birth Defects Prevention Network, January 25, 2005, Scottsdale, AZ.
22. Case studies of birth defects using registry data: examples from the literature. National Birth Defects Prevention Network. January 26, 2005, Scottsdale, AZ.
23. Teratogen Update: Pseudoephedrine. Teratology Society. June 27, 2005, St. Pete's Beach, FL.
24. Vasoactive Medications and Vascular Disruption Birth Defects. Neonatology Rounds. Beth Israel Deaconess Medical Center, October 7, 2004, Boston, MA.
25. Vasoactive Medication Use and Vascular Disruption Defects. Navigating Our Future: Aligning Strategies and Science. National Center on Birth Defects and Developmental Disabilities. July 27, 2004, Washington DC.
26. Over-the-Counter Medication Use in the National Birth Defects Prevention Study. Navigating Our Future: Aligning Strategies and Science. National Center on Birth Defects and Developmental Disabilities. July 27, 2004, Washington DC.
27. Do vasoactive exposures and vascular events affect the development of hemifacial microsomia? Epidemiology Department Research in Progress. Boston University School of Public Health. March 16, 2004, Boston, MA.
28. Environmental factors and vascular disruption defects. The 14th Fukuoka International Symposium of Perinatal Medicine. September 6-7, 2003. Kyushu University, Fukuoka, Japan.
29. Assisted reproduction and birth defects. Genetics Rounds. Massachusetts General Hospital. November 22, 2002, Boston, MA.
30. Exposure Assessment and Recall Bias. Perth Epidemiology Group. July 31, 2001, Perth, Australia.

31. Medication Use in Pregnancy in the U.S. 25th anniversary of the Birth Defects Registry of Western Australia. April 26, 2000, Perth Australia.
32. Approaches to Achieving the US Public Health Recommendation on Folic Acid. Institute for Child Health Research. April 27, 2000. Perth, Australia.
33. Medication Use in Pregnancy in the U.S. Australian Birth Defects Society. May 3, 2000 Sydney, Australia.
34. Risk Factors for Oral Clefts in Humans. International Collaborative Research on Craniofacial Anomalies. World Health Organization. November 6, 2000. Geneva, Switzerland.
35. Folic acid, multivitamins and risks of birth defects. Genetics rounds. New England Medical Center. Boston, MA.
36. Epidemiologic study of maternal risk factors for hemifacial microsomia. NIDCR Toward a Molecular Understanding of Craniofacial Morphogenesis. November 23, 1998, Bethesda, MD.
37. Maternal Smoking. Harvard Medical School Human Teratogens Course. April 29, 1996; April 14, 1997. Boston, MA.
38. Epidemiologic approaches to the study of craniofacial malformations. Harvard School of Dental Medicine Forsyth Retreat. March 1, 1997, Boston, MA.
39. Folic acid and neural tube defects. Eating Healthy: The new dietary guidelines for Americans Conference, New Hampshire Dept. of Health Human Services. November 1, 1996, Concord, NH.
40. Prepregnant weight and neural tube defects. Centers for Disease Control. Maternal Obesity and Risk for Fetal Neural Tube Defect Policy Development Meeting. September 19, 1996, Scarborough, ME.
41. Case-control study of folic acid supplementation and occurrent neural tube defects. Food and Drug Administration Hearing: Food Advisory Committee, Subcommittee on Folic Acid. November 23, 1992, Washington, DC.
42. Case-control study of folic acid supplementation and occurrent neural tube defects. New York Academy of Sciences Conference on Maternal Nutrition and Pregnancy Outcome. May 19, 1992, San Diego, CA.

CONFERENCE, SYMPOSIUM PRESENTATIONS:

1. Werler MM, Nelson K, Pober BR, Holmes LB. Recall accuracy among mothers of malformed and normal infants. *Am J Epidemiol* 1986;124:509-10. Society for Epidemiologic Research (SER) June 21. Boston, MA.
2. Rosenberg L, Werler MM, Kaufman DW, Shapiro S. Cancers of the colon and rectum in relation to reproductive factors. *Am J Epidemiol* 1987;126:760-1. SER June 16. Amherst, MA.
3. Werler MM, Mitchell AA, Shapiro S. Antenatal aspirin use and congenital heart defects. *Am J Epidemiol* 1988;128:885. SER June 14. Vancouver, BC.
4. Werler MM, Mitchell AA. Maternal cigarette smoking in relation to oral clefts. *Am J Epidemiol* 1989;130:804-5. SER June 13. Birmingham, AL.
5. Werler MM, Mitchell AA. Risk factors for gastroschisis. *Am J Epidemiol* 1991;134:747. SER June 11. Buffalo, NY.
6. Werler MM, Mitchell AA. Ovulation induction and spina bifida. *Teratology* 1992;45:467. June 27. Boca Raton, FL.
7. Werler MM, Mitchell AA. Possible recall bias in a study of folate supplementation and neural tube defects. *Am J Epidemiol* 1993;138:594. SER June 16. Keystone, CO.
8. Werler MM, Mitchell AA. Folic acid prevention and neural tube defects (NTDs): dietary contributions of folate. *Am J Epidemiol* 1994;139:54. SER June 15. Miami Beach, FL.
9. Werler MM, Louik C, Mitchell AA. Heat source exposure and neural tube defect risk. *Am J Epidemiol* 1995;142:369. SER June 21. Snowbird, UT.
10. Louik C, Werler MM, Mitchell AA. Use of a job-exposure matrix to assess occupational exposures in relation to birth defects. *Am J Epidemiol* 1995;141:S74. SER June 22. Snowbird, UT.
11. Mitchell AA, Louik C, Werler MM. Secular trends in medication use in pregnancy. *Am J Epidemiol* 1995;141:S67. SER June 23. Snowbird, UT.
12. Werler MM, Louik C, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects in offspring. *Teratology* 1995;51:Abstract #23. Teratology Society Meeting, June 25. Newport Beach, CA.
13. Werler MM, Mitchell AA. Periconceptional folic acid supplementation in relation to multiple births. *Am J Epidemiol* 1996;143:S1. SER June 13. Boston, MA.
14. Werler MM, Mitchell AA. Maternal cigarette smoking and risk of pyloric stenosis. American College of Epidemiology. September 16, 1997. Boston, MA.
15. Werler MM, Louik C, Mitchell AA. Maternal fever: teratogen or deceptogen? *Am J Epidemiol* 1998;147(Suppl):S16. SER June 24. Chicago, IL.

16. Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of risk factors for amniotic bands. *Teratology* 1999;59:388. SER June 24. Keystone, CO.
17. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and risk of cardiovascular defects and oral clefts. *Pharmacoepidemiol Drug Saf* 2000;9(Suppl 1):S84. International Society for Pharmacoepidemiology, August 16. Providence, RI.
18. Werler MM, Mitchell AA. Medication use in pregnancy in the U.S. *Teratology* 2000;62:363. Teratology Society, June 24. Palm Beach, FL.
19. Werler MM, Sheehan JE. Case-control study of hemifacial microsomia: preliminary findings. American Cleft Palate-Craniofacial Association. May 3, 2002, Seattle, WA.
20. Werler MM, Mitchell AA, Sheehan JE. Maternal vasoconstrictive exposures and risks of congenital vascular disruption defects. Society for Pediatric and Perinatal Research. June 18, 2002, Palm Desert, CA. Teratology Society. June 26, 2002, Scottsdale, AZ.
21. Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Relative risk of preeclampsia in pregnancies supported by infertility treatments. *Pharmacoepidemiol Drug Saf* 2003;12:S3. International Society for Pharmacoepidemiology, August 21. Philadelphia, PA.
22. Louik C, Werler MM, Hernández-Díaz S, Mitchell AA. Use of herbal treatments in pregnancy. *Pharmacoepidemiol Drug Saf* 2003;12:S113-4. International Society for Pharmacoepidemiology, August 22. Philadelphia, PA.
23. Werler MM, Sheehan JE, Hayes C, Mitchell AA. Maternal use of vasoactive medications and risk of hemifacial microsomia. *Pharmacoepidemiol Drug Saf* 2003;12:S135. International Society for Pharmacoepidemiology, August 23. Philadelphia, PA.
24. Werler, Louik, Hernández-Díaz, Sheehan, and Mitchell. Use of a Medication Identification Booklet for OTC Drug Reporting in a Case Control Study of Birth Defects. International Society for Pharmacoepidemiology, August 22, 2004. Bordeaux, France.
25. Werler MM, Mitchell AA. Timing, Type, and Indication of Anti-infective Use and Pregnancy Outcomes. International Society for Pharmacoepidemiology, August 19, 2007. Quebec City, Canada.
26. Werler, Hernandez-Diaz, Louik, Van Marter, Mitchell. Does antenatal hypoxia affect the risk of persistent pulmonary hypertension of the newborn? *SPER* June 21, 2006. Seattle, WA.
27. Werler MM, Mitchell AA. Observational data on the effects of antibiotics in pregnancy on birth weight and gestational age. *SPER* 2007, Boston MA
28. Dufton L, Speltz ML, Collett B, Kelly JP, Werler MM. Psychosocial status of children with hemifacial microsomia. Society of Behavioral Medicine April 7, 2010. Seattle, WA.

29. Yazdy MM, Tinker SC, Mitchell AA, Werler MM. Maternal tea consumption during pregnancy and the risk of spina bifida. SPER, June, 2011. Montreal, Canada.
30. Tinker S, Gibbs C, Devine O, Herring AH, Honein M, Crider K, Werler MM, Anderka M, Reefhuis J. Sensitivity assessment of the impact of time to maternal interview on interview quality in the National Birth Defects Prevention Study. SPER, June, 2011. Montreal, Canada.
31. Tinker S, Gibbs C, Devine O, Herring AH, Honein M, Crider K, Werler MM, Anderka M, Reefhuis J. Sensitivity assessment of the impact of time to maternal interview on interview quality in the National Birth Defects Prevention Study. SER, June 2011. Montreal, Canada.
32. Brender J, Werler M, Kelley K, Vuong A, Shinde M, Huber Jr J, Sharkey J, Zheng Q, Suarez L, Langlois P, Canfield M, Romitti P, Malik S, and the National Birth Defects Prevention Study. Nitrosatable drugs, dietary nitrites, and neural tube defects. SER, June, 2011. Montreal, Canada.
33. Margulis AV, Werler MM, Mitchell AA, Hernandez-Diaz S. Use of topiramate in pregnancy and the risk of oral clefts. ISPE, August, 2011. Chicago, IL.
34. Gilboa SM, Broussard CS, Devine O, Duwe KN, Flak AL, Boulet SL, Moore CA, Werler MM, Honein MA. Simulation model of annual spina bifida cases preventable in absence of prenatal valproate use. ISPE, August, 2011. Chicago, IL.
35. Tinker S, Gibbs C, Devine O, Herring AH, Honein M, Crider K, Werler MM, Anderka M, Reefhuis J. Sensitivity assessment of the impact of time to maternal interview on interview quality in the National Birth Defects Prevention Study. ISPE, August, 2011. Chicago, IL.
36. Yazdy MM, Tinker SC, Mitchell AA, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. 7th International Conference on Neural Tube Defects, November, 2011. Austin, TX.
37. Yazdy MM, Tinker SC, Mitchell AA, Werler MM. Maternal tea consumption during pregnancy and the risk of spina bifida. 7th International Conference on Neural Tube Defects, November, 2011. Austin, TX.
38. Parker SE, Werler MM, Shaw GM, Anderka M, Yazdy MM, and the National Birth Defects Prevention Study. Dietary glycemic index and the risk of birth defects. NBDPN/NBDPS Annual Meeting, February, 2012. Washington DC.
39. MM Yazdy, MM Werler. Comparison of web versus interview participants in a case-control study. E-epidemiology Conference, March 2012. Cariff, Wales.
40. Radin RG, Werler MM, Mitchell AA. Predictors of recall certainty of dates of analgesic medication use in pregnancy. SPER, June, 2012. Minneapolis, MN.

41. Parker SE, Yazdy MM, Tinker SC, Mitchell AA, Werler MM. The impact of folic acid intake on the association of diabetes and obesity with the risk of spina bifida. SPER, June, 2012. Minneapolis, MN.
42. Yazdy MM, Mitchell AA, Werler MM. Genitourinary infections and the risk of gastroschisis. SPER, June, 2012. Minneapolis, MN.
43. Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM. Antihyperlipidemic medication use and the risk of gastroschisis. SPER, 2012.
44. Ahrens KA, Louik C, Mitchell AA, Werler MM. Influenza vaccination during pregnancy and the risk of small for gestational age (SGA) birth. SPER, June, 2012. Minneapolis, MN.
45. Hahn KA, Collett BR, Speltz ML, Werler MM. Prenatal exposure to CNS-acting drugs and childhood neurodevelopmental outcomes. SPER, June, 2012. Minneapolis, MN.
46. Stone SL, Speltz ML, Collett B, Werler MM. Does mother know best? Predicting discrepancy in child behavior scores between mother-child and teacher-child ratings. SPER, June, 2012. Minneapolis, MN.
47. Shinde M, Vuong A, Brender J, Werler MM, Kelley KE, Huber Jr J, Sharkey J, Zheng Q, Suarez L, Langlois P, Canfield M, Romitti P, Malik S, and the National Birth Defects Prevention Study. Prenatal exposure to nitrosatable drugs, vitamin C, and risk of selected birth defects. SPER, June, 2012. Minneapolis, MN.
48. Yazdy MM, Mitchell AA, Louik C, Werler MM. Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot. ISPE, August, 2012. Barcelona, Spain.
49. Van Bennekom CM, Mitchell AA, Moore CA, Werler MM. Microtia: findings suggest no association with vasoactive medications. ISPE, August, 2012. Barcelona, Spain.
50. Mahan ST, Yazdy MM, Kasser JR, Werler MM. Is it worthwhile to routinely screen children with clubfoot for hip dysplasia? International Ponseti Conference, 2012.
51. Mahan ST, Yazdy MM, Kasser JR, Werler MM. Prenatal screening for clubfoot: what factors predict prenatal detection? International Ponseti Conference, October, 2012. Iowa City, IA.
52. Yazdy MM, Mitchell AA, Werler MM. Genitourinary infections and the risk of gastroschisis. NBDPN/NBDPS, February, 2013. Atlanta, GA.
53. Yazdy MM, Anderka M, Langlois PH, Vieira VM, Reefhuis J, Shaw GM, Feldkamp M, Bell EM, Druschel CM, Mosley BS, Romitti PA, Werler MM, and the National Birth Defects Prevention Study. Risk factors for gastroschisis occurring in temporal clusters within the National Birth Defects Prevention Study centers. NBDPN/NBDPS, February, 2013. Atlanta, GA.

54. Van Bennekom C, Mitchell AA, Moore C, Werler MM, and the National Birth Defects Prevention Study. Vasoactive exposures during pregnancy and risk of microtia. NBDPN/NBDPS, February, 2013. Atlanta, GA.
55. Werler MM, Parker SE, Yazdy MM, Mitchell AA. Epidemiologic characteristics of spina bifida cases from the Slone Epidemiology Center Birth Defects Study before and after folic acid fortification. NBDPN/NBDPS February, 2013. Atlanta, GA.
56. Mahan ST, Yazdy MM, Kasser JR, Werler MM. Is it worthwhile to routinely screen children with clubfoot for hip dysplasia? American Academy of Orthopaedic Surgeons, March, 2013. Chicago, IL.
57. Yazdy MM, Vieira VM, Langlois PH, Anderka M, Werler MM. Spatial analysis of gastroschisis in Texas and Massachusetts. SPER, June, 2013, Boston, MA.
58. Yazdy MM, Anderka M, Langlois PH, Vieira VM, Reefhuis J, Shaw GM, Feldkamp M, Bell EM, Druschel CM, Mosley BS, Romitti PA, Werler MM. Risk factors for gastroschisis occurring in temporal clusters within the National Birth Defects Prevention Study sites. SPER, June, 2013, Boston, MA.
59. Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Risk of spina bifida and maternal alcohol consumption during the first month of pregnancy according to folic acid intake. SPER, June, 2013, Boston, MA.
60. Parker SE, Starr JR, Collett BR, Speltz, ML, Werler MM. Nausea and vomiting of pregnancy and neurodevelopment in offspring. SPER, June, 2013, Boston, MA.
61. Yazdy MM, Vieira VM, Langlois PH, Anderka M, Werler MM. Spatial analysis of gastroschisis in Texas and Massachusetts. SER, June, 2013, Boston, MA.
62. Lind JN, Tinker SC, Broussard CS, Reefhuis J, Carmichael SL, Honein MA, Olney RS, Parker SE, Werler MM, and the National Birth Defects Prevention Study. Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. SER, June, 2013, Boston, MA.
63. Mahan ST, Yazdy MM, Kasser JR, Werler MM. Is it worthwhile to routinely screen children with clubfoot for hip dysplasia? Pediatric Orthopaedic Society of North America, May, 2013. Toronto, Canada.
64. Van Gelder MMHJ, Van Bennekom CM, Louik C, Werler MM, Roeleveld N, Mitchell AA. Hypertensive disorders and antihypertensive medication during pregnancy and the risk of birth defects: a case-control study. ISPE, August, 2013. Montreal, Canada.
65. Cloonan YK, Collett BR, Speltz ML, Werler MM. Sleep disordered breathing as a mediator of developmental outcomes in children with hemifacial microsomia. Submitted to Society of Research on Child Development.

DOCTORAL STUDENT ADVISING:

Kelly Getz, Ph.D. Thesis topic: Maternal Factors Shaping the Fetal Environment and the Occurrence of Autism Spectrum Disorders. 2013, Boston University, School of Public Health.

Mahsa Yazdy, Ph.D., Environmental and Infectious Risk Factors for Gastroschisis. 2013, Boston University, School of Public Health.

Katherine Ahrens, PhD. Consequences of Controlling Viral Diseases During Pregnancy: Antiherpetic Medication And Influenza Vaccination. 2012, Boston University, School of Public Health. 118. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. *Ann Epidemiol* 2012;22:799-806. Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM, and the National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. *Paediatr Perinat Epidemiol* 2013;27(4):340-5.

Mary Barger, PhD. Uterine Rupture: Risk Factors and Models for Surveillance. 2009, Boston University, School of Public Health. Barger MK, Weiss J, Nannini A, Werler MM, Heeren T, Stubblefield PG. Risk factors for uterine rupture among women who attempt a vaginal birth after a previous Cesarean: a case-control study. *J Reprod Med* 2011;56(7-8):313-20. Barger MK, Nannini A, Weiss J, Declercq ER, Stubblefield P, Werler MM, Ringer S. Severe maternal and perinatal outcomes from uterine rupture among women at term with a trial of labor. *J Perinatol* 2012;32(11):837-43.

Yahya Al-Farsi, Ph.D. Effect of High Parity on Occurrence of Pre-Diabetes, Low Birth Weight, and Anemia in Pregnancy in the Sultanate of Oman. 2008, Boston University, School of Public Health. Al-Farsi YM, Brooks DR, Werler MM, Cabral HJ, Wallenburg HC, Al-Shafei MA. Effect of high parity on the occurrence of pre-diabetes: a cohort study. *Acta Obstet Gynecol Scand* 2010;89(9):1182-6. Al-Farsi YM, Brooks DR, Werler MM, Cabral HJ, Al-Shafei MA, Wallenburg HC. Effect of high parity on occurrence of anemia in pregnancy: a cohort study. *BMC Pregnancy Childbirth* 2011;11(1):7. Al-Farsi YM, Brooks DR, Werler MM, Cabral HJ, Al-Shafei MA, Wallenburg HC. Effect of high parity on occurrence of some fetal growth indices: a cohort study. *Int J Womens Health* 2012;4:289-93.

Alissa Caton, Ph.D. Antihypertensive medication use and the risk of cardiovascular malformations and severe hypospadias in the National Birth Defects Prevention Study. 2003-2006, SUNY-Albany. Caton AR, Bell EM, Druschel CM, Werler MM, Mitchell AA, Browne ML, McNutt LA, Romitti PA, Olney RS, Correa A, and the National Birth Defects Prevention Study. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. *Birth Defects Res A Clin Mol Teratol* 2008;82(1):34-40. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, McNutt LA, Romitti PA, Mitchell AA, Olney RS, Correa A, and the National Birth Defects Prevention Study. Antihypertensive medication

use during pregnancy and the risk of cardiovascular malformations. *Hypertension* 2009;54(1):63-70.

Rachel Badovinac, D.M.D., Sc.D. Oral clefts: Methods for elucidating environmental and genetic risk factors. 2002-2006, Harvard School of Public Health-School of Dental Medicine. Badovinac R, Werler M, Williams P, Kelsey K, Hayes C. Folic Acid-Containing Supplement Consumption During Pregnancy and Risk for Oral Clefts: A Meta-Analysis. *Birth Defects Research Part A: Clinical and Molecular Teratology* (In press).

William McQuade, M.P.H., D.Sc. Assessing the impact of routine preventive care on health outcomes in a Medicaid population continuously enrolled in managed care. 2002-2006, BUSPH.

Katie Meyers, M.P.H., Sc.D. Oral clefts, alcohol, smoking, study design, and misclassification. 2000-2002, HSPH. Meyer KA, Werler MM, Hayes C, Mitchell AA. Low maternal alcohol consumption during pregnancy and oral clefts in offspring: The Slone Birth Defects Study. *Birth Defects Research (Part A)* 2003;67:509-14. Meyer KA, Williams P, Hernandez-Diaz S, Cnattingius S. Smoking and the risk of oral clefts: exploring the impact of study designs. *Epidemiology*. 2004 15:671-8.

Sowmya Rao, D.Sc. Inference for multiwave surveys with nonresponse. 1999-2001, BUSPH. Rao RS, Glynn RJ, Werler MM, Van Bennekom CM, Mitchell AA. Comparison of alternative survey methods for sensitive self-reported behaviors in a follow-up study of isotretinoin. *J Epidemiol Biostat* 2000;5:133-6.

Sonia Hernandez-Diaz, M.D., Sc.D. Folic acid antagonists and risk of birth defects. 1998-2000, HSPH. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. *Am J Epidemiol* 2001;153:961-8. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 2000;343:1608-14.

Susi Lieff, M.S.W., M.P.H., Ph.D. Cigarette smoking and oral clefts. 1992-1996, UNC-SPH. Lieff S, Olshan AF, Werler M, Savitz DA, Mitchell AA. Selection bias and the use of controls with malformations in case-control studies of birth defects. *Epidemiology* 1999;10:238-41. Lieff S, Olshan AF, Werler M, Strauss RP, Smith J, Mitchell A. Maternal cigarette smoking during pregnancy and risk of oral clefts in newborns. *Am J Epidemiol* 1999;150:683-94.

Catherine Hayes, D.M.D., D.M.Sc. Folic acid/multivitamins and oral clefts. 1990-1993, HSPH-SDM. Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. *Am J Epidemiol* 1996;143:1229-34.

CURRENT STUDENTS:

Samantha Parker, MPH. Thesis topic: The Impact of Endometrial Injury to the Risk of Preeclampsia

SERVICE/GRANT REVIEWS/SCIENTIFIC ADVISORY PANELS:

- 1/14-6/14 Editor, Data Sharing Committee, National Birth Defects Prevention Study
- 6/13- Epidemiology Congress of the Americas planning committee
- 6/13 NIEHS, Board of Scientific Counselors Review, Epidemiology Branch
- 6/13- Data Safety Monitoring Board, Folic Acid and Zinc Supplementation Trial, NICHD
- 10/12, 9/08 NICHD, Site Review, Div. of Epidemiology, Statistics, & Prevention Research
- 6/12- Executive Board, Society for Pediatric and Perinatal Epidemiology Research
- 1/12-present Scientific Advisory Board, Cimzia (Certolizumab pegol) Pregnancy Registry, UCB
- 1/11- Scientific Advisory Board, Tocilizumab Pregnancy Registry, Genentech
- 6/09-6/10 Teratology Society Nominations and Elections Committee
- 7/07-7/12 Data Safety Monitoring Board, Effects of Aspirin in Gestation and Reproduction Trial, NICHD
- 1/06- Scientific Advisory Board, Abatacept Pregnancy Registry, Bristol Meyers Squibb
- 10/06 National Institute for Child Health and Human Development research contract review, Chair
- 7/06 Special Emphasis Panel, ZHD1 DRG-A, National Institute for Child Health and Human Development research contract review, Chair.
- 7/06 Special Emphasis Panel, National Institute for Dental and Craniofacial Research U01 review
- 6/06 NIH Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Review Group
- 4/06 NIH Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions member conflict review
- 3/06 National Institute for Child Health and Human Development Concept Clearance Review
- 3/06 NIH Chronic Disease Epidemiology Review Group

- 1/06 Centers for Disease Control and Prevention, Prioritizing a Research Agenda for Oral Clefts, Chair, epidemiology section
- 11/05 NIH Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions (member conflict review)
- 6/05 United Kingdom Research Capacity Development review
- 4/05 National Institute for Child Health and Human Development Loan Repayment Program review
- 1/05- Scientific Advisory Board, Rheumatic Disease & Psoriasis Pregnancy Registry, Amgen. Chair
- 1/04- Scientific Advisory Board, Abbott Adalimumab Pregnancy Registry, Abbott Laboratories
- 11/04 NIH Chronic Disease Epidemiology (member conflict review), Chair
- 3/04 National Institute for Child Health and Human Development Special Emphasis Panel
- 7/03 National Institute for Child Health and Human Development research contract review, Chair
- 6/03 NIH, Epidemiology & Disease Control (member conflict review)
- 3/03 NIH, Social Sciences, Nursing, Epidemiology and Methods (member conflict review)
- 11/02 National Institute for Child Health and Human Development Concept Clearance Review
- 4/02 National Institute for Child Health and Human Development Concept Clearance Review
- 4/02 NIH, Epidemiology & Disease Control (member conflict review)
- 11/01 NIH, Epidemiology & Disease Control (member conflict review)
- 6/01-6/02 Teratology Society Publications Committee
- 6/01-6/02 Teratology Society Clark Fraser Award Committee
- 3/00 NIH, Epidemiology & Disease Control (member conflict review)
- 1/99 NIH, Epidemiology & Disease Control (member conflict review)

- 11/99- Scientific Advisory Board, Leflonomide Pregnancy Outcomes Study, Aventis/Sonofi
- 10/98-6/02 NIH, Epidemiology and Disease Control 1 Study Section, Full member
- 6/98-6/99 Teratology Society Nominations and Elections Committee
- 6/96-6/00 Member-at-Large, Society for Pediatric and Perinatal Epidemiology Research
- 6/96-6/98 NIH, Epidemiology and Disease Control 1 Study Section, Ad hoc reviewer
- 8/9/96 NIH, Epidemiology & Disease Control (member conflict review)
- 9/96-12/02 Methods Committee National Birth Defects Prevention Study
- 7/94 Office of Disease Prevention and Health Promotion, Preventive Services Task Force, reviewer
- 5/94 NIDR, Special Emphasis Panel, Contract reviewer
- 11/92 DHHS-FDA Food Advisory Subcommittee on Folic Acid
- 3/90 NICHD research contract review
- 6/88-6/91 Founding Member-at-Large, Society for Pediatric and Perinatal Epidemiology Research

SOCIETIES:

- 1988- Teratology Society
- 1987- Society for Pediatric and Perinatal Epidemiologic Research
- 1982- Society for Epidemiologic Research

EDITORIAL BOARD MEMBERSHIP AND PEER REVIEW:

- 9/03- Editorial Board member, *Paediatric and Perinatal Epidemiology*
- 1/03- Associate Editor, Birth Defects Research: Clinical and Molecular Teratology (formerly known as *Teratology*)

GRANT APPLICATIONS NOT FUNDED:

NIH / NICHD (Principal Investigator) 12/01/11-11/30/16
Epidemiology study of risk factors for amyoplasia-type arthrogryposis
The goal of this study is to identify pregnancy risk factors for amyoplasia through a large-scale epidemiologic investigation.

NIH (Principal Investigator) 04/01/03-03/31/07
Gene-Environment Interaction in Craniosynostosis
This study was to examine medication use, cigarette smoking, and genetic factors in relation to the risk of craniosynostosis.

NIH (Principal Investigator) 04/01/03-09/30/05
Descriptive Epidemiology of Hemangioma
The major goal was to identify demographic and reproductive factors associated with the occurrence of hemangiomas.

March of Dimes (Principal Investigator) 6/1/01-5/31/02
Descriptive Epidemiology of Hemangioma

MANUSCRIPT REVIEWS: New England Journal of Medicine, Journal of the American Medical Association, American Journal of Epidemiology, Epidemiology, The Lancet, American Journal of Obstetrics and Gynecology, Birth Defects Research Part A (formerly Teratology), Obstetrics and Gynecology, Public Health Nutrition, Paediatric and Perinatal Epidemiology, Cleft Palate-Craniofacial Journal, American Journal of Medical Genetics, National Birth Defects Prevention Network Annual Report, Journal of Obstetrics and Gynaecology Research, Clinical Biochemistry, Statistics in Medicine, Human Reproduction, PLOS-1